GEREF
LOE Approachingsermorelin acetate
NDAINJECTIONINJECTABLE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEREF (sermorelin acetate) is an injectable synthetic analog of growth hormone-releasing hormone (GHRH) approved in 1990. It stimulates the anterior pituitary to release endogenous growth hormone. The drug is indicated for patients with growth hormone deficiency, typically children with inadequate endogenous GH secretion.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), this mature product likely operates with a lean, stable team focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GEREF offers limited career momentum given zero linked job opportunities and an LOE-approaching lifecycle. This role is best suited for mid-career professionals seeking stable, low-pressure management of a legacy product rather than high-growth visibility.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.